nivolumab,ipilimumab
bms
['hcrn,gu16,260', 'hcrn,gu,16,260', 'nivolumab', 'nivo', 'biomarker', 'renal,(-adrenal)', 'rcc,(-irccs),(-srcc),(-urcc)']
 nourhan el ahmar, md of presents the abstract biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (rcc) enrolled in the hcrn gu16-260 trial. 
An independent nonprofit cancer research organization conducting multi-center investigator-initiated oncology studies since 1984.